Viagra DP by Dragon Pharma

Dragon Pharma Sexual Health

Sildenafil

Viagra DP•50 mg/tab
Class PDE5 Inhibitor
Half-Life ~3–5 hours
Onset 30–60 minutes
Duration 4–6 hours
FDA Approval Yes — ED and Pulmonary Hypertension
Form Oral Tablet
Manufactured by Dragon Pharma Third-Party Tested
Availability: In Stock
$75.00
Quantity
Shipping
  • International
  • U.S. Domestic
Wishlist

Sildenafil (Viagra DP) 50mg — PDE5 Inhibitor by Dragon Pharma

Sildenafil (Viagra DP) is Dragon Pharma's formulation of the first-in-class PDE5 inhibitor at 50mg per tablet — the original pharmaceutical treatment for erectile dysfunction, approved by the FDA in 1998 and the most extensively studied drug in men's sexual health. Sildenafil was discovered through serendipity rather than design: originally investigated as a treatment for angina and hypertension, its unexpected erectogenic effect was observed during Phase I clinical trials by participants who declined to return unused tablets. The compound's specific PDE5 inhibition mechanism — concentrating its effect in the high-PDE5-expressing smooth muscle of the corpus cavernosum — makes it the most targeted vascular intervention for erectile dysfunction available.

Also searched as: Viagra DP 50mg, Sildenafil 50mg, Dragon Pharma Sildenafil, Sildenafil tablets, generic Viagra.

How Sildenafil Works — The cGMP Cascade

The complete PDE5 inhibition mechanism is rarely explained accurately in competitor content:

  • Sexual arousal causes parasympathetic nerve terminals and endothelial cells in the penis to release nitric oxide (NO). NO diffuses into the smooth muscle cells of the corpus cavernosum (the erectile tissue of the penis)
  • Inside smooth muscle cells, NO activates guanylate cyclase — an enzyme that converts GTP to cyclic GMP (cGMP). Elevated cGMP activates protein kinase G, which phosphorylates and opens potassium channels, hyperpolarises the cell, and causes smooth muscle relaxation
  • Smooth muscle relaxation allows blood inflow to the lacunar spaces of the corpus cavernosum to dramatically increase, compressing venous outflow and producing erection
  • PDE5 (phosphodiesterase type 5) is the enzyme that breaks down cGMP — returning smooth muscle to contracted state and ending erection. The corpus cavernosum has exceptionally high PDE5 expression compared to most other tissues — this is why PDE5 inhibitors are so tissue-selective in their erectile effect
  • Sildenafil competitively inhibits PDE5 — it occupies the PDE5 active site, preventing cGMP breakdown. cGMP levels remain elevated longer; smooth muscle relaxation and penile blood flow are enhanced and sustained. Critically: Sildenafil enhances the response to sexual stimulation — it does not produce erection in the absence of arousal-driven NO release

The Discovery Story — Angina Drug to Erectile Dysfunction Treatment

Sildenafil's history is one of the most celebrated examples of serendipitous drug discovery:

  • Pfizer chemists synthesised Sildenafil (UK-92480) in 1989 as part of a cardiovascular programme targeting PDE5 in cardiac tissue — the goal was treating angina and hypertension by relaxing vascular smooth muscle to reduce cardiac workload
  • Phase I/II trials in Wales in the early 1990s showed the compound was a modest antihypertensive — not the remarkable cardiac drug hoped for. However, male trial participants consistently reported unexpected penile erections as a "side effect"
  • Pfizer redirected the programme toward erectile dysfunction — at the time an undertreated condition without an effective oral treatment. The clinical development that followed produced Viagra (1998 FDA approval), which became one of the fastest-selling pharmaceutical products in history
  • Sildenafil's additional approval for pulmonary arterial hypertension (as Revatio) followed — confirming that PDE5 inhibition in pulmonary vasculature produces clinically meaningful vasodilation in a non-genital context

Sildenafil vs Tadalafil — The Key Comparison for AAS Users

Parameter Sildenafil (Viagra DP) Tadalafil (Cialis DP)
Half-life ~3–5 hours ~17.5 hours
Duration of effect 4–6 hours 24–36 hours
Onset 30–60 minutes 30–60 minutes
Food interaction High-fat meals delay absorption — take fasted No significant food interaction
Dosing flexibility As-needed only; short window As-needed or daily low-dose
PDE11 selectivity issue Minimal PDE11 activity Some PDE11 inhibition — potential testicular concern
Colour vision effect Blue tinge (PDE6 inhibition) possible at higher doses Minimal PDE6 effect
Best use Planned sexual activity; specific timing needed Spontaneous activity; on-cycle daily dosing

AAS-Related Erectile Dysfunction — Why PDE5i Sometimes Helps and Sometimes Doesn't

This is the most relevant and least discussed aspect of Sildenafil for the AAS user population:

  • AAS cause erectile dysfunction through multiple mechanisms, and PDE5 inhibitors address only the vascular component:
  • Vascular ED (Sildenafil works): AAS-induced dyslipidaemia and vascular endothelial damage reduce NO bioavailability. Sildenafil's PDE5 inhibition compensates for reduced cGMP by preventing its breakdown — effective when NO production is partially intact
  • Hormonal ED — low testosterone post-cycle (Sildenafil partially helps): Testosterone is required for NO synthase activity in penile tissue. Profoundly low testosterone reduces the NO signal that Sildenafil depends on. Sildenafil provides some benefit but is less effective without adequate androgen environment — HCG, PCT and testosterone recovery are the primary interventions
  • Hormonal ED — elevated estrogen on-cycle (Sildenafil partially helps): Elevated estrogen blunts the central arousal signals that drive NO release. PDE5i helps with the penile vascular component but cannot address the CNS arousal deficit from estrogen imbalance — AI management is the primary intervention
  • Prolactin-elevated ED (Sildenafil less effective): Elevated prolactin from 19-nor AAS (Nandrolone, Trenbolone) significantly suppresses libido and arousal at the central level — producing a pattern of normal penile anatomy but absent arousal drive where PDE5i is minimally effective; cabergoline is the primary intervention

Effects and Benefits

  • Enhanced erection quality — PDE5 inhibition sustains cGMP elevation, enhancing and prolonging the erectile response to sexual stimulation
  • Onset 30-60 minutes — predictable timing for planned sexual activity
  • 4-6 hour effective window — adequate for most use scenarios without the extended duration of Tadalafil
  • FDA-approved pharmaceutical compound — decades of safety data across tens of millions of users
  • AAS context: partial management of vascular and hormonal ED components on-cycle

Dosage and Administration

Dose Timing Notes
25 mg (½ tablet) 30–60 min before sexual activity Starting dose; assess response
50 mg (1 tablet) 30–60 min before sexual activity Standard effective dose for most users
100 mg (2 tablets) 30–60 min before sexual activity Maximum recommended dose; increases side effect risk

Take on an empty stomach or after a light meal — high-fat meals significantly delay Sildenafil absorption and delay onset. Maximum one dose per 24 hours. The 50mg tablet can be halved for the 25mg starting dose.

Critical contraindication — nitrates. Sildenafil is absolutely contraindicated with nitrate medications (glyceryl trinitrate, isosorbide mononitrate/dinitrate, amyl nitrite/poppers). Combined use causes severe, potentially fatal hypotension. Do not use Sildenafil if taking any nitrate medication in any form.

Side Effects

  • Headache — most common; from systemic vasodilation; typically mild
  • Flushing — vasodilation effect; face and neck warmth
  • Visual disturbances — blue/green tinge, increased light sensitivity at higher doses from PDE6 inhibition in retinal photoreceptors; transient
  • Nasal congestion — vasodilation in nasal mucosa
  • Hypotension — particularly with alpha-blockers, antihypertensives, or alcohol; caution required
  • Priapism — prolonged erection (>4 hours) is a medical emergency; very rare at standard doses

Related Products

  • Cialis DP (Tadalafil) — longer-acting PDE5 inhibitor; 24-36 hour duration; on-cycle daily dosing option; no food interaction
  • Levitra (Vardenafil) — similar duration to Sildenafil; potentially faster onset; slightly different PDE5 selectivity profile
  • Cock Bombs — combined Sildenafil + Tadalafil formulation for dual-mechanism coverage

"Sildenafil was the accidental discovery that redirected a failed angina drug into one of the best-selling pharmaceuticals in history — its PDE5 inhibition in the corpus cavernosum's cGMP pathway is the most precisely characterised mechanism in ED treatment, with 25+ years of safety data across tens of millions of male users."

Storage and Handling

Store Sildenafil at room temperature, away from direct sunlight and moisture. Keep in original packaging until use.

Please log in to write review.

Sexual arousal triggers nitric oxide (NO) release from penile nerve terminals and endothelial cells. NO activates guanylate cyclase in corpus cavernosum smooth muscle cells, converting GTP to cyclic GMP (cGMP). Elevated cGMP causes smooth muscle relaxation, dramatically increasing blood inflow to the erectile tissue while compressing venous outflow — producing erection. PDE5 normally breaks down cGMP and terminates this process. Sildenafil competitively inhibits PDE5, sustaining cGMP levels and prolonging smooth muscle relaxation. Critically, Sildenafil amplifies the response to sexual arousal but does not produce erection in its absence — NO release from arousal is required.

Pfizer's chemists synthesised Sildenafil (UK-92480) in 1989 targeting PDE5 in cardiac and vascular smooth muscle for treating angina and hypertension — relaxing blood vessels to reduce cardiac workload. Early trials in Merthyr Tydfil, Wales showed modest antihypertensive effects. Male participants consistently reported penile erections as a side effect and declined to return unused tablets — an observation that redirected the entire programme. Pfizer recognised the commercial and clinical opportunity in ED (then largely untreated) and developed Sildenafil specifically for this indication, gaining FDA approval in 1998 as Viagra.

AAS-induced erectile dysfunction has multiple causes, and Sildenafil addresses only the vascular component. When ED results from reduced NO bioavailability (vascular damage from dyslipidaemia), Sildenafil works well. When caused by profoundly low testosterone post-cycle, Sildenafil's effectiveness is limited — testosterone is required for penile NO synthase activity, and without adequate androgen the NO signal that Sildenafil depends on is insufficient. When caused by elevated prolactin from 19-nor AAS (Trenbolone, Nandrolone), cabergoline addresses the central arousal deficit that Sildenafil cannot. And when elevated estrogen blunts CNS arousal, AI management is the primary intervention.

Nitrates. Sildenafil is absolutely contraindicated with any nitrate medication — glyceryl trinitrate (GTN, nitroglycerin), isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite/alkyl nitrites ("poppers"). Both PDE5 inhibitors and nitrates lower blood pressure through complementary vasodilatory mechanisms — the combination causes severe, potentially fatal hypotension. This interaction is not dose-dependent: even a single dose of Sildenafil with any nitrate can produce life-threatening blood pressure collapse.

Sildenafil's 4-6 hour window suits planned sexual activity where timing is predictable — take 30-60 minutes beforehand. Tadalafil's 24-36 hour duration suits spontaneous activity and daily low-dose protocols (on-cycle daily dosing for continuous PDE5 support). Sildenafil requires taking on an empty stomach or after a light meal — high-fat meals significantly delay absorption. Tadalafil has no meaningful food interaction. If on-cycle daily PDE5 management is the goal, Tadalafil's pharmacokinetics are more practical; for specific occasion use with predictable timing, Sildenafil's shorter window and faster clearance are appropriate.

Generally yes — there are no documented pharmacokinetic interactions between Sildenafil and commonly used AAS. The main on-cycle consideration is that AAS cycles often involve elevated blood pressure from water retention (with aromatising compounds) or direct vascular effects — Sildenafil itself causes vasodilation and blood pressure reduction, which may compound or partially offset AAS-related hypertension. Monitor blood pressure; do not use with any antihypertensive medication combination without medical guidance.

Related Products